Does Wegovy, Mounjaro or Ozempic Cause Hair Loss? A Simple Explanation

Wegovy, Mounjaro and Ozempic are GLP-1 medications commonly used for weight management. As their use has increased, so have reports of hair shedding – leading many people to worry that the medication itself is causing hair loss.
​

The important thing doctors want you to know is this:
​

Wegovy and Mounjaro do not directly damage hair follicles.
​

Instead, hair shedding associated with these medications is usually caused by rapid weight loss, not the drug itself.
​

This type of hair loss is most often a form of telogen effluvium – a temporary, reversible condition triggered by physical stress on the body.
​

This explanation also applies to Ozempic, which contains a similar active ingredient and can cause the same effect when used for weight loss.
​

Weight-loss-related hair loss is a temporary increase in hair shedding that occurs when the body undergoes a significant change – such as rapid weight loss.
​

Hair follicles are sensitive to changes in:

When weight loss happens quickly, more hairs enter the shedding phase of the hair cycle.
​

Doctors see hair shedding with weight loss treatments for a few key reasons:
​

Rapid weight loss
​

Fast weight loss is one of the most common triggers for telogen effluvium. The quicker the weight drops, the more likely shedding is to occur.
​

Reduced calorie intake
​

Significantly lowering calories can temporarily deprive hair follicles of the energy they need to stay in the growth phase.
​

Nutrient shortfalls
​

Protein, iron, zinc, biotin and vitamin D are all essential for hair growth. During rapid weight loss, levels can fall if intake isn’t carefully managed.
​

Physiological stress
​

Even positive changes – like weight loss – are still a form of stress to the body, which can disrupt the hair cycle.
​

Hair shedding does not usually begin immediately.

A typical timeline looks like this:

This delay is why many people don’t initially connect hair shedding to earlier weight loss.
​

Weight-loss-related hair loss usually presents as diffuse shedding, not bald patches.
​

Common signs include:

Importantly, this type of shedding:

No – but it can overlap.
​

Weight-loss-related hair loss

Pattern hair loss (androgenetic alopecia)

In some people, rapid weight loss can reveal underlying pattern hair loss that was previously subtle. This is why persistent thinning should be assessed.
​

Read more: What is Male Pattern Hair Loss? A Simple Explanation.
​

Read more: What is Female Pattern Hair Loss? A Simple Explanation.
​

In most cases, yes.
​

Once:

…the hair growth cycle usually resets and regrowth begins.
​

However, regrowth takes time. Hair grows slowly – around 1 cm per month – so visible improvement may take several months.
​

Doctors recommend focusing on the basics:
​

Adequate protein intake
​

Hair is made of protein. Ensuring enough protein in your diet is critical during weight loss.
​

Nutritional support
​

Iron, vitamin D, zinc and biotin levels should be optimised if low.
​

Gentle hair care
​

Avoid tight styles, aggressive brushing and excessive heat.
​

Stress management
​

Poor sleep and ongoing stress can prolong shedding.
​

Clinical review if needed
​

If shedding is severe, prolonged or distressing, a clinician can help confirm the diagnosis and rule out other causes.
​

It’s worth speaking to a clinician if:

Early assessment helps ensure the right cause is being treated.
​

Hair shedding while taking Wegovy, Mounjaro or Ozempic can be alarming – but for most people, it’s a temporary response to rapid weight loss, not permanent hair loss.

Doctors want to reassure you:

Understanding what’s happening can make the process far less frightening – and help you focus on recovery rather than panic.
​

1.Alabduljabbar K, Alsaqaaby M, Neff KJ, Crotty M, le Roux CW. Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine. 2024 Feb;83(2):392-398.
​

2. Bracchiglione J, Meza N, Franco JV, Escobar Liquitay CM, Novik A V, Ocara Vargas M, Lazcano G, Poloni D, Rinaldi Langlotz F, Roqué-Figuls M, Munoz SR, Madrid E. Semaglutide for adults living with obesity. Cochrane Database Syst Rev. 2025 Oct 30;10(10):CD015092.
​

3. Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disord. 2025 Oct;11(5):416-423.